Rapid-acting interventions in treatment-resistant depression – a comparative review of esketamine and psilocybin

Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz, Mikołaj Zbrożek, K. Biłyk, Maciej Hutkowski, Zuzanna Chwostek, Hanna Maruchniak, Wiktoria Marzec, Paulina Biedroń

Journal of Pre-Clinical and Clinical Research May 12, 2026 DOI: 10.26444/jpccr/221219 (opens in new tab)

Read Full Text

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Depression Esketamine Psilocybin

Abstract

Rapid-acting interventions in treatment-resistant depression – a comparative review of

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review International Journal of Molecular Sciences September 28, 2022 36 citations
Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression Zenodo (CERN European Organization for Nuclear Research) July 17, 2026
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of Affective Disorders April 1, 2024 19 citations
Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review Journal of Education Health and Sport November 29, 2025
Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials. Cureus April 1, 2025 1 citation

Explore topics

Depression Esketamine Psilocybin

By condition and practice

Esketamine for depression Ketamine for depression Psilocybin for depression

Study at a glance

Abstract

Related reading

Explore topics

By condition and practice